Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Suite 455
Rockville
Maryland
20850
United States
Tel: 240-268-5300
Fax: 240-268-5310
Website: http://www.rexahn.com/
Email: biojob@rexahn.com
219 articles about Rexahn Pharmaceuticals, Inc.
-
Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
11/5/2020
Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly after 4:00 pm (EST) today, Thursday, November 5, 2020
-
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
11/2/2020
Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn’s stockholders approved all of the proposals presented, including: (i) the issuance of shares of Rexahn common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated June 17, 2020, as amended, by and among Rexahn, Razor Merger Sub, Inc. and Ocuphire Pharma, Inc. (“Ocuphire”) and
-
Rexahn and Ocuphire Enter into Definitive Merger Agreement
6/18/2020
Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates
-
Clinical Catch-Up: April 6-10
4/13/2020
It was a very busy week for clinical trial news. Here’s a look. -
Rexahn said it notified Merck on April 7 of its decision to discontinue the development of RX-5902 for the treatment of metastatic triple-negative breast cancer.
-
Rexahn Reports Data From the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
2/12/2018
The poster presentation reported interim data on the Phase 2a clinical trial of RX-3117 monotherapy for the treatment of advanced bladder cancer.
-
Rexahn Pharmaceuticals Announces Collaboration With Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin) for the Treatment of Hepatocellular Carcinoma
2/8/2018
Haichang will develop a nano-liposomal formulation of RX-0201 using its proprietary QTsome technology and conduct certain pre-clinical and clinical activities through completion of a Phase IIa proof-of-concept clinical trial for the treatment of HCC.
-
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin)
1/29/2018
The allowed application will extend the patent protection for uses claimed under this patent until 2036.
-
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
1/22/2018
The poster presentation reported the final data on the Phase IIa study of RX-3117 monotherapy in metastatic pancreatic cancer.
-
Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer
1/4/2018
Mr. Swirsky was most recently President, CEO and a director of GenVec.
-
Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium
12/11/2017
Supinoxin enhances the efficacy of immunotherapy in multiple preclinical models.
-
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane in Patients Newly Diagnosed With Metastatic Pancreatic Cancer
11/8/2017
Abraxane (albumin-bound paclitaxel) is commonly used in the treatment of pancreatic cancer in combination with other chemotherapies.
-
Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/6/2017
Rexahn's cash and investments totaled approximately $23.2 million as of September 30, 2017, compared to approximately $20.3 million as of December 31, 2016.
-
Rexahn Pharmaceuticals, Inc. Announces $8 Million Registered Direct Offering
10/13/2017
-
Rexahn Pharmaceuticals, Inc. Receives Positive Opinion From EMA For Orphan Drug Designation For RX-3117
10/10/2017
-
Rexahn Pharmaceuticals, Inc. Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The 2017 European Society For Medical Oncology (ESMO) Congress
9/11/2017
-
Rexahn Pharmaceuticals, Inc. Presents Final Data From The Supinoxin Phase I Clinical Study And New Preclinical Data On RX-3117 At The 2017 European Society For Medical Oncology (ESMO) Congress
9/11/2017
-
Rexahn Pharmaceuticals, Inc. Announces Retirement Of Its Founder, Chang Ahn, Ph.D., From The Board Of Directors
9/1/2017
-
Rexahn Pharmaceuticals, Inc. Receives New U.S. Patent For Supinoxin
8/30/2017
-
Rexahn Pharmaceuticals, Inc. Issues Mid-Year Shareholder Letter To Review Recent Progress And Clinical Plans
8/14/2017